Heart Failure Progression During Cardiotoxic Chemotherapy

Cardiotoxicity, often used to describe a decline in left ventricular ejection fraction (LVEF) related to potentially cardiotoxic chemotherapy, occurred in 9% of a cohort of 2,625 patients receiving anthracycline therapy, with the highest incidence observed within the first year after chemotherapy